Cosentyx (secukinumab)
$2,331.63
This medicine requires a prescription. See “Prescription Guide”.
We can only help if the medicine is not available in your country. Learn more.
Price Frequently Asked Questions Details Patient stories Import guides
Cosentyx (secukinumab) is indicated for the treatment of adults with:
- Moderate to severe plaque psoriasis.
- Active psoriatic arthritis (PsA).
- Active ankylosing spondylitis (AS).
This medicine is not (yet) part of our standard product range but we may be able to get it for you. The packaging size and strength below may vary due to product availability. Please contact us to verify price and availability.
Cosentyx (secukinumab)
Cosentyx (secukinumab) is indicated for the treatment of adults with:
– moderate to severe plaque psoriasis
– active psoriatic arthritis (PsA)
– active ankylosing spondylitis (AS)
Approved presentations:
150 mg/mL in packs containing 1 or 2 sensoready pens
150 mg/mL in packs containing 1 or 2 single-use prefilled syringes
Please see full prescribing information and available presentations at:
[2] Summary of Product Characteristics (EMA): Cosentyx (secukinumab) [PDF], Novartis, October 2019. [3] Product Monograph (Health Canada): Cosentyx (secukinumab) [PDF], Novartis, July 2019.
[4] Summary of Product Characteristics (TGA): Cosentyx (secukinumab) [PDF], Novartis, August 2019. [5] Product detail (Medsafe): Cosentyx (secukinumab) [PDF], Novartis, August 2019.
Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about it’s approval in a specific country feel free to contact our support team.
| 1 Injection solution pre-filled syringe x 300 mg/mL | 2,331.63 |
|---|
Be the first to review “Cosentyx (secukinumab)”
Related products
Psoriatic Arthritis
Psoriatic Arthritis
Psoriatic Arthritis
Reviews
There are no reviews yet.